BridgeBio Pharma (BBIO) Other Working Capital Changes (2018 - 2026)

BridgeBio Pharma has reported Other Working Capital Changes for 6 years, with the latest figure at -$1.9 million in Q1 2026.

• Quarterly Other Working Capital Changes fell 25.99% year-over-year to -$1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.9 million (down 19.94% YoY) and the FY2025 annual result came in at -$6.5 million, down 10.93% from the prior year.
• Other Working Capital Changes fell to -$1.9 million in Q1 2026 per BBIO's latest filing, from -$1.8 million in the prior quarter.
• Over five years, Other Working Capital Changes peaked at $24.0 million in Q1 2024 and troughed at -$18.6 million in Q4 2025.
• A 5-year average of $555764.7 and a median of -$313000.0 in 2025 frame the typical range for Other Working Capital Changes.
• The sharpest annual moves came in 2022 and 2023: Other Working Capital Changes plunged 36.02% in 2022, then soared 31.32% in 2023.
• Over 5 years, Other Working Capital Changes stood at -$1.4 million in 2022, then grew by 18.79% to -$1.2 million in 2023, then retreated by 24.61% to -$1.4 million in 2024, then decreased by 24.05% to -$1.8 million in 2025, then decreased by 3.46% to -$1.9 million in 2026.
• According to Business Quant data, Other Working Capital Changes over the past three periods registered -$1.9 million, -$1.8 million, and -$1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.